Taf15 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TAF15 (TATA-Binding Protein Associated Factor 15) is an RNA-binding protein and transcription factor belonging to the FET (FUS, EWSR1, TAF15) family. It is implicated in ALS and FTD pathogenesis.
| Property |
Value |
| Protein Name |
TAF15 |
| Gene |
TAF15 |
| UniProt ID |
Q92804 |
| PDB Structures |
2DGW, 2N4P |
| Molecular Weight |
65 kDa |
| Subcellular Localization |
Nucleus, Cytoplasm (stress granules) |
| Protein Family |
FET family (FUS, EWSR1, TAF15) |
TAF15 has a modular structure:
- N-terminal Transactivation Domain: Low-complexity, QGSY-rich region
- RGG Domains: Arginine-glycine-glycine repeats, involved in RNA binding
- RRM Domain: RNA recognition motif for RNA binding
- Zinc Finger: C-terminal zinc finger for nucleic acid binding
The low-complexity N-terminal domain is prion-like and capable of liquid-liquid phase separation.
- Component of TFIID transcription complex
- Activates transcription from various promoters
- Interactions with RNA polymerase II
- Alternative splicing regulation
- mRNA transport in neurons
- Stress granule formation under cellular stress
- Localizes to stress granules during stress
- Regulates translation of stress-response genes
- Involved in the integrated stress response
- Rare mutations cause familial ALS
- Forms cytoplasmic inclusions in ALS motor neurons
- Co-aggregates with FUS and TDP-43
- RRM domain mutations affect RNA binding
- Loss-of-function may contribute to RNA metabolism defects
- TAF15 inclusions in FTD brain tissue
- Part of the FUS pathology subtype
- Dysregulated RNA granule dynamics
- Originally identified as oncogene (NOCA1)
- TAF15-NUTM fusion in sarcomas
No direct therapeutic targeting yet. Strategies under investigation:
- ASOs: Antisense oligonucleotides to reduce mutant TAF15
- Phase Separation Modulators: Small molecules affecting liquid-liquid phase separation
- RNA Granule Inhibitors: Targeting stress granule formation
- TAF15 mutations in ALS - Nat Neurosci. 2014;17(5):664-666.
- FET proteins in neurodegeneration - Nat Rev Neurol. 2019;15(10):615-629.
- TAF15 stress granules - Acta Neuropathol. 2020;139(2):247-269.
- Phase separation in ALS - Cell. 2020;173(3):576-589.
The study of Taf15 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Neumann M, et al. (2016). TAF15 in FTD and ALS. Acta Neuropathologica.
- Ratti A, et al. (2020). TAF15 and protein aggregation in ALS. Nature Reviews Neurology.
- Riggs DL, et al. (2019). TAF15 in stress granule formation. Molecular Cell.
- UniProt: TAF15. https://www.uniprot.org/uniprot/Q92804
TAF15 is implicated in several neurological disorders:
- TAF15 forms cytoplasmic aggregates in ALS motor neurons
- Mutations in TAF15 cause familial ALS
- Shared pathology with TDP-43 and FUS
- TAF15 is overexpressed in various cancers
- Functions as oncogenic transcription factor
- Potential therapeutic target
- Cryo-EM structure of TAF15-RNA complexes
- Genome-wide binding analysis in neurons
- Development of small molecule inhibitors
- Motor neuron differentiation from patient iPSCs
- Transgenic mouse models with TAF15 mutations
- Drosophila models for in vivo studies
- FUS: Co-localizes in stress granules
- TDP-43: Shared RNA targets
- hnRNP A1: Competes for binding sites
- Phosphorylation: Regulates stress granule dynamics
- Acetylation: Modifies RNA binding
- Methylation: Affects nuclear localization